Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novozymes A/S Confirms FY 2013 Earnings Guidance and Raises FY 2013 Sales Guidance


Thursday, 25 Apr 2013 02:00am EDT 

Novozymes A/S announced that its outlook for full year 2013 is maintained on all lines with the exception of an increase in the expectation for sales (revenue) growth in DKK to between 5% and 8%, up from between 4% and 7% at previous guidance. EBIT growth expectation is maintained at between 4% and 7%. The 2013 expectation for the EBIT margin is maintained at around 24%. Net profit is still expected to grow by between 6% and 9%. For the fiscal year 2012, the Company reported revenue of DKK 11,234 million, EBIT of DKK 2,745 million and reported net profit of DKK 2,015 million. According to I/B/E/S Estimates, analysts on average are expecting the Company to report revenue of DKK 11,986.84 million, EBIT of DKK 2,925.48 million and reported net profit of DKK 2,188.71 million for the fiscal year 2013. 

Company Quote

263.6
2.3 +0.88%
19 Dec 2014